<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>15(1)</volume><submitter>Inoue H</submitter><pubmed_abstract>The advent of immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway has revolutionized cancer treatment, resulting in improved clinical outcomes. However, resistance remains a critical challenge. This study aimed to comparatively elucidate immunophenotypic changes in syngeneic mouse models sensitive (MC-38) or resistant (LLC1) to anti-PD-1 monoclonal antibody (mAb) treatment. In the sensitive MC-38 model, anti-PD-1 therapy increased dendritic cells (DCs) and macrophages, while decreasing myeloid-derived suppressor cells (MDSCs) within the tumor microenvironment. Enhanced expression of antigen presentation molecules (MHC I/II) and costimulatory molecules (CD80/CD86) was observed on tumor-associated DCs and macrophages. Tumor-infiltrating CD4&lt;sup>+&lt;/sup>T, CD8&lt;sup>+&lt;/sup>T, regulator</pubmed_abstract><journal>Scientific reports</journal><pagination>8311</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11894063</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Comprehensive immunophenotyping reveals distinct tumor microenvironment alterations in anti-PD-1 sensitive and resistant syngeneic mouse model.</pubmed_title><pmcid>PMC11894063</pmcid><pubmed_authors>Ebi N</pubmed_authors><pubmed_authors>Fujita M</pubmed_authors><pubmed_authors>Hamasaki T</pubmed_authors><pubmed_authors>Nakao A</pubmed_authors><pubmed_authors>Minomo H</pubmed_authors><pubmed_authors>Inoue K</pubmed_authors><pubmed_authors>Nagata I</pubmed_authors><pubmed_authors>Inoue H</pubmed_authors><pubmed_authors>Horai N</pubmed_authors></additional><is_claimable>false</is_claimable><name>Comprehensive immunophenotyping reveals distinct tumor microenvironment alterations in anti-PD-1 sensitive and resistant syngeneic mouse model.</name><description>The advent of immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway has revolutionized cancer treatment, resulting in improved clinical outcomes. However, resistance remains a critical challenge. This study aimed to comparatively elucidate immunophenotypic changes in syngeneic mouse models sensitive (MC-38) or resistant (LLC1) to anti-PD-1 monoclonal antibody (mAb) treatment. In the sensitive MC-38 model, anti-PD-1 therapy increased dendritic cells (DCs) and macrophages, while decreasing myeloid-derived suppressor cells (MDSCs) within the tumor microenvironment. Enhanced expression of antigen presentation molecules (MHC I/II) and costimulatory molecules (CD80/CD86) was observed on tumor-associated DCs and macrophages. Tumor-infiltrating CD4&lt;sup>+&lt;/sup>T, CD8&lt;sup>+&lt;/sup>T, regulator</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Mar</publication><modification>2025-04-04T20:26:00.244Z</modification><creation>2025-04-04T20:26:00.244Z</creation></dates><accession>S-EPMC11894063</accession><cross_references><pubmed>40064915</pubmed><doi>10.1038/s41598-025-91979-w</doi></cross_references></HashMap>